HSBC Holdings’s Fulcrum Therapeutics FULC Stock Holding History

HSBC Holdings’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$442K	Buy	58,636 +15,374	+36%	+$143K	﹤0.01%	2279
2025 Q4	$498K	Sell	43,262 -10,544	-20%	-$107K	﹤0.01%	2316
2025 Q3	$474K	Buy	53,806 +4,270	+9%	+$30.9K	﹤0.01%	2133
2025 Q2	$357K	Sell	49,536 -25,425	-34%	-$136K	﹤0.01%	2336
2025 Q1	$219K	Sell	74,961 -998	-1%	-$3.67K	﹤0.01%	2577
2024 Q4	$355K	Buy	75,959 +26,944	+55%	+$99.4K	﹤0.01%	2391
2024 Q3	$178K	Buy	+49,015	New	+$364K	﹤0.01%	2659
2024 Q2	–	Sell	-149,627	Closed	-$1.41M	–	3018
2024 Q1	$1.41M	Buy	+149,627	New	+$1.34M	﹤0.01%	1635

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

HSBC Holdings's FULC Position: Q1 2026 in Review

HSBC Holdings increased its Fulcrum Therapeutics (FULC) stake by 36% in Q1 2026, buying an estimated $143K and bringing the position to 58,636 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #2279.

HSBC Holdings first reported a position in FULC in Q1 2024 and has held it in 8 quarters since. The position peaked at $1.41M in Q1 2024. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

HSBC Holdings held 58,636 shares of Fulcrum Therapeutics worth $442K as of Q1 2026.
HSBC Holdings bought 15,374 Fulcrum Therapeutics shares in Q1 2026, an estimated $143K.
Fulcrum Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2279 holding.
HSBC Holdings first reported a position in Fulcrum Therapeutics in Q1 2024 and has held it in 8 quarters since.
HSBC Holdings's Fulcrum Therapeutics position peaked at $1.41M in Q1 2024.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.